High-dose 131I-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin's lymphoma: Adjusting radiation absorbed dose to actual organ volumes

Journal of Nuclear Medicine

Volumn 45, Issue 6, 2004, Pages 1059-1064

  Rajendran, Joseph G ^a,c   Fisher, Darrell R ^b   Gopal, Ajay K ^c   Durack, Lawrence D ^a   Press, Oliver W ^c   Eary, Janet F ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b PACIFIC NORTHWEST NATIONAL LABORATORY   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Internal dosimetry; MIRD models; Non Hodgkin's lymphoma; Patient specific dosimetry; Radioimmunotherapy

Indexed keywords

IODINE 131; TOSITUMOMAB I 131; IODINE 131 ANTI B1 ANTIBODY; IODINE-131 ANTI-B1 ANTIBODY; MONOCLONAL ANTIBODY; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG ABSORPTION; DRUG MEGADOSE; FEASIBILITY STUDY; FEMALE; HUMAN; ISOTOPE LABELING; MAJOR CLINICAL STUDY; MALE; ORGAN SIZE; PHANTOM; PRIORITY JOURNAL; RADIATION ABSORPTION; RADIATION DOSE; RADIOIMMUNOTHERAPY; SCINTILLATION CAMERA; STATISTICAL SIGNIFICANCE; ANTIBODY SPECIFICITY; BODY BURDEN; CLINICAL TRIAL; COMPARATIVE STUDY; COMPUTER ASSISTED RADIOTHERAPY; KIDNEY; LIVER; LUNG; METABOLISM; METHODOLOGY; MIDDLE AGED; NONHODGKIN LYMPHOMA; RADIATION RESPONSE; RADIOMETRY; RELATIVE BIOLOGIC EFFECTIVENESS; SPLEEN; TISSUE DISTRIBUTION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; BODY BURDEN; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HUMANS; KIDNEY; LIVER; LUNG; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; ORGAN SIZE; ORGAN SPECIFICITY; RADIOIMMUNOTHERAPY; RADIOMETRY; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RELATIVE BIOLOGICAL EFFECTIVENESS; SPLEEN; TISSUE DISTRIBUTION;

EID: 3242740406     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Argatoff LH, Connors JM, Klasa RJ, Horsman DE, Gascoyne RD. Mantle cell lymphoma: a clinicopthologic study of 80 cases. Blood. 1997;89:2067-2078.
2. Freedman AS, Neuberg D, Gribben JG, et al. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody purged autologous bone marrow transplantation in Mantle cell lymphoma: no evidence for long term remission. J Clin Oncol. 1998;16:13-18.
3. Armitage JO. Treatment of non-Hodgkin's lymphoma. N Engl J Med. 1993;328:1023-1030.
4. Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Catovsky D. Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J Clin Pathol. 1998;51:364-369.
5. Press OW, Eary JF, Gooley T, et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood. 2000;96:2934-2942.
6. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet. 1995;346:336-340.
7. Gopal AK, Rajendran JG, Petersdorf SH, et al. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood. 2002;99:3158-3162.
8. Eary JF, Appelbaum F, Durack LD, et al. Preliminary validation of the opposing view method for quantitative gamma camera imaging. Med Phys. 1989;16:362-387.
9. Eary JF, Press OW, Badger CC, et al. Imaging and treatment of B-cell lymphoma. J Nucl Med. 1990;31:1257-1268.
10. Vose JM, Wahl RL, Saleh M, et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2000;18:1316-1323.
11. Kaminski MS, Fig LM, Zasadny KR, et al. Imaging, dosimetry and radioimmunotherapy with iodine-131-labeled anti-CD37 antibody in B-cell lymphoma. J Clin Oncol. 1992;10:1696-1711.
12. DeNardo SJ, DeNardo GL, O'Grady LF, et al. Treatment of B-cell malignancies with 131-I Lym-1 monoclonal antibodies. Int J Cancer. 1988;3:96-101.
13. Eary JF, Krohn KA, Press OW, Durack L, Bernstein ID. Importance of pretreatment radiation absorbed dose estimation for radioimmunotherapy of non-Hodgkin's lymphoma. Nucl Med Biol. 1997;24:635-638.
14. Loevinger R, Budinger TF, Watson EE. MIRD Primer. New York, NY: Society of Nuclear Medicine; 1991:
15. Fisher DR. Internal dosimetry for systemic radiation therapy. Semin Radiat Oncol. 2000;10:123-132.
16. Fisher DR. Radiation dosimetry for radioimmunotherapy: an overview of current capabilities and limitations. Cancer. 1994;73:905-911.
17. Williams LE, Liu A, Raubitschek AA, Wong JY. A method for patient-specific absorbed dose estimation for internal beta emitters. Clin Cancer Res. 1999;5:3015s-3019s.
18. Fowler JF. Radiobiological aspects of low dose rates in radioimmunotherapy. Int J Radiat Oncol Biol Phys. 1990;18:1261-1269.
19. Liu SY, Eary JF, Petersdorf SH, et al. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol. 1998;16:3270-3278.
20. Leichner PK, Akabani G, Colcher D, et al. Patient-specific dosimetry of indium-111- and yttrium-90-labeled monoclonal antibody CC49. J Nucl Med. 1997;38:512-516.
21. 90Y-labeled B72.3 GYK-DTPA immunoconjugate in beagle dogs. Nucl Med Biol. 1993;20:571-578.
22. Behr TM, Griesinger F, Riggert J, et al. High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support: results of a pilot study. Cancer. 2002;94:1363-1372.
23. Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol. 1999;17:3793-3803.
24. Kaminski MS, Zasadny KR, Francis IR, et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol. 1996;14:1974-1981.
25. 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma. J Nucl Med. 2000;41:952-958.
26. DeNardo GL, Juweid ME, White CA, Wiseman GA, DeNardo SJ. Role of radiation dosimetry in radioimmunotherapy planning and treatment dosing. Crit Rev Oncol Hematol. 2001;39:203-218.
27. 166Ho-DOTMP in myeloablative treatment of multiple myeloma: pharmacokinetics, biodistribution, and absorbed dose estimation. J Nucl Med. 2002;43:1383-1390.
28. Virgolini I, Britton K, Buscombe J, Moncayo R, Paganelli G, Riva P. In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med. 2002;32:148-155.
29. Bernard BF, Krenning EP, Breeman WA, et al. D-Lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake. J Nucl Med. 1997;38:1929-1933.
30. Schiano TD, Bodian C, Schwartz ME, Glajchen N, Min AD. Accuracy and significance of computed tomographic scan assessment of hepatic volume in patients undergoing liver transplantation. Transplantation. 2000;69:545-550.
31. Heymsfield SB, Fulenwider T, Nordlinger B, Barlow R, Sones P, Kutner M. Accurate measurement of liver, kidney, and spleen volume and mass by computerized axial tomography. Ann Intern Med. 1979;90:185-187.
32. Stabin MG. Internal dosimetry in the use of radiopharmaceuticals in therapy: science at a crossroads? Cancer Biother Radiopharm. 1999;14:81-89.
33. Paracelsus. Four Treatises of Theophrastus von Hohenheim Called Paracelsus. Sigerist H et al., trans. Baltimore, MD: Johns Hopkins University Press; 1996. [Paracelsus is the author; Sigerist is the translater.]